Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Read the rest here:
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Saint-Herblain (France), January 12, 2021 – Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001. VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

Read more from the original source:
Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

TORONTO and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today an outline of its strategic priorities and action plan for 2021.

See the original post here:
ProMIS Neurosciences Announces Strategic Priorities for 2021

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.

See the article here:
Adamas to Present at Upcoming H.C. Wainwright Conference

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.

Visit link:
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. EST.

Read more here:
Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Monday, January 11, 2021.

Originally posted here:
Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 p.m. Eastern Time.

See the rest here:
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Robert F. Dolski appointed as Chief Financial Officer

Originally posted here:
Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company’s board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the departures of Jessica Hopfield, Ph.D. and Tony Rosenberg, who stepped down from the board on December 31, 2020 after years of service.

More here:
Radius Health Announces Change to its Board of Directors

Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.

See the rest here:
Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group

Company developing novel small molecule protein degraders for intractable diseases Company developing novel small molecule protein degraders for intractable diseases

Original post:
Ligature Therapeutics Launches, Raises USD $6M in Seed Financing

VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Lui Franciosi of Franciosi Consulting Ltd. has been intrigued with the growing interest in the use of psychedelic drugs for treating depression, anxiety and addiction. He has been reviewing the scientific literature and the history of these drugs to better understand their merit. The most commonly mentioned drugs and promising alternatives for patients unresponsive to traditional treatments are ayahuasca, psilocybin, dimethyltryptamine (DMT), or lysergic acid diethylamide (LSD). These psychedelics appear to be well-tolerated with the most common adverse effects being transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure. Overall, they seem to be effective in reducing many disease symptoms. However, the scientific consensus is that even though these substances demonstrate rapid, sustained and well tolerated therapeutic effects with single or even a few doses, there is still a need for large-scale, randomised controlled studies to elucidate their potential safety and use in clinical practice.

See the original post:
Franciosi Consulting Reviewing the Science and History of Psychedelic Drug Use for Treating Depression, Anxiety and Addiction

Company Announcement

The rest is here:
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to progress IPH6101/SAR443579 into investigational new drug (IND)-enabling studies. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format (Gauthier et al. Cell 2019).

Read the original:
Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Basel, 5 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations. Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomised data from the phase II CITYSCAPE trial. CITYSCAPE provides the first evidence that targeting both immune inhibitory receptors, TIGIT and PD-L1, may enhance anti-tumour activity by potentially amplifying the immune response.1

Original post:
Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung...

The rest is here:
Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021

ALLSCHWIL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern Standard Time.

Read more:
Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

COPENHAGEN, Denmark, January 5, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has entered into contracts with three European governments for the supply of IMVANEX® smallpox vaccine.

Read more:
Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Investors can pre-register for the event here

Read the original post:
AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event